- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05611632
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial (NHS-Galleri)
A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat.
The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, controlled trial to assess the performance and clinical utility of a multi-cancer early detection test for population screening in the UK when added to standard of care. Participants and the study teams remain blinded throughout the study with the exception of the study nurses returning the results and a small number of staff to enable them to perform administrative duties. Blinding is maintained for participants with the exception of those participants who test positive. Those who test positive will be informed by designated trial staff and will be referred for standard of care investigations and treatment. Trial sponsor employees, the CIs and site staff (unless identified differently in the blinding plan for study conduct needs) will remain blinded throughout the study.
Randomization will be to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
Unless diagnosed with cancer, participants in both arms will be asked to return for annual visits at approximately 12 and 24 months. All participants whether test positive, test negative or not tested will be followed for cancer and associated outcomes via NHS dataset linkages.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Chester, United Kingdom
- EMS Healthcare Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be at 50-77 years of age, inclusive, at the time of data extraction from NHS datasets or GP records used to identify potential participants; and
- Capable of giving signed and legally effective informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Consent provided by a legally authorised representative is not permitted in this protocol.
Exclusion Criteria:
- Previous or current participation in another GRAIL-sponsored study.
- Personal history of invasive cancer or haematologic malignancy, diagnosed within the three years prior to expected enrolment date. Note: Individuals with a diagnosis of non-melanoma skin cancer and prostate cancer patients whose only treatment is active surveillance are NOT excluded
- Definitive treatment for invasive cancer or haematologic malignancy within the 3 years prior to expected enrolment date, including adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer).
- Currently taking demethylating or cytotoxic agents for any condition.
- Undergoing current investigation for suspected cancer, defined as having been referred to a two week wait clinic or undergoing investigations at an RDC or other clinic with a stated suspicion of cancer.
- Currently on a palliative care pathway.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
Blood collection and multi-cancer early detection testing with return of positive test results.
|
Blood collection and multi cancer early detection testing with return of positive test results.
Other Names:
|
No Intervention: Control
Blood collection only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
absolute numbers of stage III and IV cancers diagnosed
Time Frame: 3-4 years after randomization
|
3-4 years after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
absolute numbers of advanced cancers (stage III and IV cancers or one that results in a cancer-specific death) diagnosed
Time Frame: 3-4 years after randomization
|
3-4 years after randomization
|
|
absolute numbers of stage IV cancers diagnosed
Time Frame: 1 years after randomization
|
1 years after randomization
|
|
absolute numbers of stage IV cancers diagnosed
Time Frame: 3-4 years after randomization
|
3-4 years after randomization
|
|
cancer-specific mortality for a pre-specified group of cancer types
Time Frame: 3-4 years after randomization
|
3-4 years after randomization
|
|
cancer-specific mortality
Time Frame: up to 8 years after randomization
|
up to 8 years after randomization
|
|
proportion of Stage I and II cancers
Time Frame: 3-4 years after randomization
|
3-4 years after randomization
|
|
test performance (sensitivity, specificity, positive predictive value, negative predictive value) and cancer signal origin accuracy) in the intervention arm.
Time Frame: Up to 3 years
|
Up to 3 years
|
|
number of follow up procedures and invasive procedures, complications and deaths associated with follow-up diagnostic procedures in all test positive cases
Time Frame: Up to 3 years
|
Up to 3 years
|
|
number and type of invasive procedures performed in false positive cases
Time Frame: Up to 3 years
|
Up to 3 years
|
|
radiation exposure measured in mSv per participant due to test result directed evaluations in all test positive cases
Time Frame: Up to 3 years
|
Up to 3 years
|
|
psychological impact using the short form State Trait Anxiety Index-6 questionnaire (a six item validated measure of state anxiety), at various timepoints in all test positive cases
Time Frame: Up to 3 years
|
Scores range from 20-80 with the general population expected to score 34-36 and very high anxiety classed as scoring > 49.
|
Up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
healthcare resource utilisation
Time Frame: Up to 3 years
|
The data collected may be used to conduct future exploratory economic analyses, and will include: Number and types of medical encounters and cancer-specific diagnostic and treatment procedures, including clinical lab visits, imaging tests, invasive tests, and clinic visits.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Liz Holmes, GRAIL, LLC
Publications and helpful links
General Publications
- Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, Swanton C, Sasieni P. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022 Oct 1;14(19):4818. doi: 10.3390/cancers14194818.
- Sasieni P, Smittenaar R, Hubbell E, Broggio J, Neal RD, Swanton C. Modelled mortality benefits of multi-cancer early detection screening in England. Br J Cancer. 2023 Apr 25. doi: 10.1038/s41416-023-02243-9. Online ahead of print.
- Brentnall AR, Mathews C, Beare S, Ching J, Sleeth M, Sasieni P. Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri. Clin Trials. 2023 Apr 24:17407745231167369. doi: 10.1177/17407745231167369. Online ahead of print.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GRAIL-009
- ISRCTN91431511 (Registry Identifier: ISRCTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Multi-cancer early detection test (Galleri test)
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityShanghai Weihe Medical Laboratory Co., Ltd.Not yet recruitingPRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection (PROFUTURE)Neoplasms | CancerChina
-
GRAIL, LLCRecruitingCancer | Early Detection of CancerUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Guangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Cancer Institute and Hospital, Chinese Academy...Guangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Zhujiang HospitalGuangzhou BRCompletedHepatobiliary MalignanciesChina
-
GRAIL, LLCCompleted
-
Shanghai Zhongshan HospitalGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Shanghai Zhongshan HospitalGuangzhou Burning Rock Dx Co., Ltd.Completed
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting
-
ClearNote HealthNot yet recruitingPancreatic CancerUnited States